Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Do | G Sachs Slightly Cuts SINOPHARM TP to $21.17; 1Q Results Weak | 5 | AASTOCKS | ||
29.04. | SINOPHARM 1Q NP Falls 10.7% to RMB1.42B | 7 | AASTOCKS | ||
29.04. | SINOPHARM Plunges ~10% as 1Q24 Profit Wanes 10.7% | 14 | AASTOCKS | ||
29.04. | SINOPHARM (01099): ANNOUNCEMENT PROPOSED CENTRALIZED REGISTRATION FOR THE ISSUE AMOUNT OF NON-FINANCIAL CORPORATE DEBT FINANCING INSTRUMENTS | 3 | HKEx | ||
29.04. | SINOPHARM (01099): ANNOUNCEMENT QUARTERLY FINANCIAL INFORMATION FOR THE THREE MONTHS ENDED 31 MARCH 2024 | 4 | HKEx | ||
26.04. | SINOPHARM (01099): 2023 SUSTAINABILITY REPORT | 2 | HKEx | ||
26.04. | SINOPHARM (01099): ANNUAL REPORT 2023 | 6 | HKEx | ||
25.04. | SINOPHARM (01099): ANNOUNCEMENT PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM (CNCM LTD) FOR THE FIRST QUARTER ENDED 31 MARCH ... | 5 | HKEx | ||
25.04. | SINOPHARM (01099): ANNOUNCEMENT PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM ACCORD FOR THE FIRST QUARTER ENDED 31 MARCH ... | 3 | HKEx | ||
16.04. | SINOPHARM (01099): NOTICE OF BOARD MEETING | 117 | HKEx | ||
12.04. | Aktie der Sinopharm Group läuft heute schlechter (2,31 €) | 176 | ARIVA.de | Im Minus liegt aktuell die Aktie der Sinopharm Group . Das Papier kostete zuletzt 2,31 Euro. Die Sinopharm Group-Aktie verzeichnet derzeit einen Kursverlust von 3,63 Prozent. Sie hat sich um 9 Cent... ► Artikel lesen | |
03.04. | Sinopharm Group-Aktie leicht im Minus (2,393 €) | 257 | ARIVA.de | Im Wertpapierhandel notiert die Sinopharm Group-Aktie gegenwärtig leichter. Das Wertpapier notiert aktuell bei 2,39 Euro. Das Wertpapier der Sinopharm Group verzeichnet zur Stunde einen Abschlag von... ► Artikel lesen | |
20.03. | SINOPHARM (01099): ANNOUNCEMENT PRINCIPAL ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM (CNCM LTD) FOR THE YEAR ENDED 31 DECEMBER 2023 | 5 | HKEx | ||
14.03. | SINOPHARM (01099): ANNOUNCEMENT PRELIMINARY FINANCIAL DATA OF SINOPHARM ACCORD FOR THE YEAR OF 2023 | 8 | HKEx | ||
12.03. | SINOPHARM (01099): ANNOUNCEMENT COMPLETION OF CHANGE OF REGISTERED ADDRESS | 2 | HKEx | ||
12.03. | SINOPHARM (01099): NOTICE OF BOARD MEETING | 4 | HKEx | ||
22.02. | China TCM's Shares Pop Over 20% After Sinopharm Makes USD2.2 Billion Take-Private Offer | 9 | Yicai Global | ||
22.02. | Sinopharm offers to take Hong Kong-listed China-TCM private in nearly US$3 billion deal | 11 | South China Morning Post | ||
21.02. | Sinopharm offers to take China-TCM private in nearly $3 billion deal | 5 | Reuters | ||
08.02. | SINOPHARM (01099): NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED SHAREHOLDERS-ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | 4 | HKEx |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
TAAT GLOBAL ALTERNATIVES | 0,168 | +11,67 % | TAAT Global Alternatives Inc (2): TAAT Global settles $80,415 debt with shares | ||
SINOPHARM | 2,344 | -0,04 % | G Sachs Slightly Cuts SINOPHARM TP to $21.17; 1Q Results Weak | ||
MERCK KGAA | 152,65 | +0,43 % | Dividendenbekanntmachungen (29.04.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 361 DEGREES INTERNATIONAL LTD KYG884931042 0,139 HKD 0,0166 EUR ACROW LIMITED AU0000006124 0,0285 AUD 0,0174 EUR AGNC INVESTMENT... ► Artikel lesen | |
BAYER | 27,950 | -0,25 % | Bayer: Erneut unter Beschuss | Bayer sieht sich weiterhin den rechtlichen Auseinandersetzungen rund um das umstrittene Unkrautvernichtungsmittel Glyphosat sowie PCB-Chemikalien entgegen. Zu den bereits vorhandenen Problemen gesellt... ► Artikel lesen | |
ASTRIA THERAPEUTICS | 9,550 | +2,14 % | Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update | BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported... ► Artikel lesen | |
SCHOTT PHARMA | 37,960 | 0,00 % | EQS-News: SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma ernennt Tobias Erfurth zum Leiter Investor Relations | EQS-News: SCHOTT Pharma AG & Co. KGaA
/ Schlagwort(e): Personalie
SCHOTT Pharma ernennt Tobias Erfurth zum Leiter Investor Relations
30.04.2024 / 17:00 CET/CEST
Für... ► Artikel lesen | |
NOVO NORDISK | 114,80 | +0,68 % | Ihre wichtigsten Termine: Apple, Linde, Kerry Group, Shell, Novo Nordisk & Hugo Boss legen Q-Zahlen vor! | © Foto: UnsplashGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:00 Uhr, Deutschland:... ► Artikel lesen | |
AQUESTIVE THERAPEUTICS | 3,520 | +7,32 % | Aquestive stock falls amid Libervant approval, Anaphylm update | ||
LYRA THERAPEUTICS | 4,030 | -12,96 % | Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update | WATERTOWN, Mass., April 30, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company developing long-acting, anti-inflammatory... ► Artikel lesen | |
OMNIAB | 4,670 | +1,52 % | OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights | EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2023, and provided operating and partner program... ► Artikel lesen | |
ELI LILLY | 685,50 | +0,29 % | Vor den Earnings: Verhageln die Engpässe bei der Abnehmspritze die Earnings für Eli Lilly? | © Foto: Sascha Lotz/dpaDer Erfolg der begehrten Blockbuster Mounjaro und Zepbound könnte Eli Lilly zum Verhängnis werden und für eine negative Überraschung bei den Quartalszahlen sorgen. US-Pharmariese... ► Artikel lesen | |
ALLARITY THERAPEUTICS | 1,000 | -18,70 % | Allarity Therapeutics, Inc.: Allarity Therapeutics' Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer | Boston (May 2, 2024)-Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today... ► Artikel lesen | |
SOLID BIOSCIENCES | 10,100 | -1,27 % | Solid Biosciences Inc.: Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CHARLESTOWN, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases... ► Artikel lesen | |
HARROW | 10,385 | -2,40 % | Harrow Health, Inc. Announces Fourth Quarter and Year-End 2023 Financial Results | NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, announced results for the fourth quarter and year ended December 31, 2023. The Company also... ► Artikel lesen | |
NEUROGENE | 36,630 | +3,50 % | Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates | NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases... ► Artikel lesen |